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The treatment of prostate cancer
patients is plagued by the heteroge-
neous clinical behavior of cancers rang-
ing from indolent tumors requiring no
intervention to aggressive tumors result-
ing in patient mortality. Exemplary of the
difficulties arising from such heterogene-
ity are the results of the randomized trial
of surgery versus observation (Holmberg
et al., 2002). In this study, where surgery
was associated with a 50% reduction in
hazard ratio of death from prostate can-
cer, the absolute reduction in mortality
was a modest 6.6% suggesting that the
benefit of surgery was confined to a sub-
population of men. Thus, there is a criti-
cal need to define unique prostate can-
cer subgroups differing with respect to
clinical outcome.
A number of clinical and pathologi-
cal features including the preoperative
prostate-specific antigen (PSA) level,
the clinical stage, and the state of tumor
differentiation (Gleason Score), can
stratify patients into subgroups differing
with respect to outcome after surgery
and are widely used to guide clinical
decision making. In the era of PSA-
based cancer detection, patients are
increasingly presenting within a narrow
range of these parameters and as such
these measures are beginning to lose
their discriminatory power.
Molecular approaches to this prob-
lem have focused on candidate gene
analysis in tissue-based assays. The
loss of expression of genes with tumor
suppressor activities including p27,
PTEN, and E-cadherin has been associ-
ated with disease progression or with
higher grade tumors, while overexpres-
sion or amplification of putative onco-
genes including Her-2/neu, Bcl-2, myc,
and cyclin D1 has been noted in 
aggressive androgen-independent dis-
ease (reviewed in Thomas and Loda,
2002). However, none has gained wide-
spread use in clinical practice.
The lack of progress in defining use-
ful molecular markers and in under-
standing the deregulated biological
processes driving prostate cancer cell
transformation has led to the application
of genomic approaches to this problem.
Microarray expression experiments
have identified a number of additional
molecular markers including hepsin,
AMACR, PIM-1 kinase (Dhanasekaran
et al., 2001; Magee et al., 2001; Welsh et
al., 2001), or expression-based models
as potential indicators of disease or pre-
dictors of disease progression (Singh et
al., 2002).
Varambally et al. (2002) using cDNA
microarray analysis compared the gene
expression patterns found in benign
prostate tissue, organ-confined tumors,
and androgen-independent metastatic
prostate tumors—the penultimate lethal
form of the disease. Here, they found that
the polycomb group (PcG) protein
enhancer of zeste homolog (EZH2) was
among a group of transcripts whose
increased expression distinguished
metastatic tumors from those localized to
the prostate. The authors show that the
expression of both the EZH2 mRNA and
protein progressively increase from
benign to organ-confined, to metastatic
tumors, suggesting that increases in
EZH2 precede the development of
metastatic foci. These data raise the pos-
sibility that EZH2 protein levels might
prove useful in predicting patient out-
come after prostatectomy. Indeed,
immunohistochemical analysis of the
EZH2 protein in tissue microarrays pre-
dicted outcome independently of
Gleason Score, presurgical PSA, and
stage. If validated in larger datasets these
data could provide important additional
information useful in patient stratification.
During development PcG proteins
are required to maintain the appropriate
silencing or repression of homeotic
genes through the recruitment of chro-
matin modifiers to Polycomb response
elements and are opposed in action by
the trithorax group of proteins (TrxG).
More specifically while TrxG proteins
maintain the activated state of Hox
genes in the appropriate developmental
segments, PcG genes generate herita-
ble states of gene silencing over extend-
ed regions of chromatin to prevent inap-
propriate Hox gene expression.
The protein products of the PcG fam-
ily form two distinct complexes one con-
taining EZH2/EED and a second
HPC/HPH complex containing BMI1, an
oncogene that cooperates with myc in
lymphomagenesis and is amplified in
mantle cell lymphoma.While gene ampli-
fication or direct transformation by mem-
bers of EZH2/EED complex have not yet
been demonstrated, EZH2 overexpres-
sion has been observed in lymphoma
(reviewed in Jacobs and van Lohuizen,
2002). Moreover, EZH2 overexpression
has been linked to increases in prolifera-
tion (Visser et al., 2001) whereas anti-
sense inhibition of EZH2 has been asso-
ciated with decreases in DNA synthesis
(Fukuyama et al., 2000). Similarly, in
prostate cells Varambally et al. show that
RNAi-mediated EZH2 knockdown leads
to growth inhibition in cell culture and
that this may be linked to alterations in
the cell-cycle profile. These data sug-
gest, but do not constitute definitive evi-
dence of a link between EZH2 activity
and either the process of cellular trans-
formation or the induction of a metastatic
phenotype. Thus, a necessary step is to
determine whether EZH2 has transform-
ing activity or can confer metastatic
potential. In addition, evidence that
EZH2 is targeted by specific genetic
alterations, such as gene amplification,
would likewise bolster the argument that
EZH2 expression is functionally relevant
in prostate cancer.
The molecular mechanisms that
might link PcG proteins such as BMI1 and
EZH2 or TrxG proteins to the process 
of transformation remain unclear.
EZH2/EED clearly functions as a tran-
scriptional repressor complex and may do
so by recruiting histone deacetylase or
histone methyltransferase activities to
chromatin (Cao et al., 2002; van der Vlag
and Otte, 1999). TrxG complexes are
associated with transcriptional activation,
and in human leukemia the TrxG gene
MLL is a major target of translocation.
However, in some cases such transloca-
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tions create MLL-fusion proteins that
recruit PcG repressors to promoters
(reviewed in Jacobs and van Lohuizen,
2002). These data suggest the intriguing
possibility that overexpression or amplifi-
cation or PcG proteins such as BMI1 
and EZH2 participate in transformation
through their native transcriptional repres-
sion activities while the TrxG protein MLL
may transform through the acquisition of
PcG-like repressor activities.
In leukemia a number of transloca-
tions often involving transcription factors,
are recognized as having created novel
fusion proteins strongly linked to the
development of the disease. Notable
among these are the AML1-ETO and
PML-RARα fusions which generate
unique transcriptional repressor pro-
teins. Moreover, in mouse models of
leukemia recent data suggest the possi-
ble utility of treating this disease by
reversing transcriptional repression with
histone deacetylase inhibitors (He et al.,
2001). These data have led to the initia-
tion of clinical trials in selected leukemia
patients. The implication that aberrant
EZH2 transcriptional repression mediat-
ed through histone deacetylase may
contribute to or drive aggressive forms of
prostate cancer, raises the possibility
that novel “transcription”-based thera-
peutics might find clinical utility in the
treatment of this disease.
If transcriptional repression by EZH2
seems a likely molecular mechanism
through which growth advantage is
obtained, what are the genes targeted
for repression? Here, Varambally et al.
use transcriptional profiling in cell cul-
ture systems to identify a number of
putative EZH2 repressed transcripts.
However, surprisingly the authors did
not show whether such targets were
corepressed in the expression profiles
from the metastatic human prostate
tumors. Among the downregulated
genes were numerous solute trans-
porters, but otherwise no strong func-
tional themes emerged.
Based on the currently available data
EZH2 transcriptional repression may be
linked to a deregulation of cell prolifera-
tion. Nonetheless, an alternative model
is worth considering. In acute leukemia,
emerging data suggests that specific
translocations, typically involving tran-
scription factors, induce a block in
myeloid differentiation and cooperate
with those translocations triggering
kinase activation to induce full-blown
leukemia (Deguchi and Gilliland, 2002).
In prostate cancer, alterations in differen-
tiation are clearly evident and less well-
differentiated tumors are associated with
a poor outcome. To date, no mechanism
accounting for this apparent block has
been elucidated. Given the role of PcG
proteins in blocking the differentiation
program during development through
gene repression, a possibility worth
exploring is that EZH2 overexpression
may act to promote prostate cancer
development through the initiation of
inappropriate block to prostate epithelial
cell differentiation.
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